Schrodinger launched Bunsen, an agentic AI co-scientist that marries its physics-based molecular simulation platform with large language models to accelerate drug discovery. The early-access release targets research teams seeking to run complex molecular modeling workflows through a conversational interface.
Bunsen builds on Schrodinger’s existing computational chemistry tools and wraps them in an AI layer that understands scientific objectives, devises computational strategies and executes multi-step discovery pipelines autonomously. The system self-corrects in real time and can run concurrent studies across multiple drug programs.
“Bunsen removes friction from the discovery cycle, enabling greater throughput and expanding the user base for our computational platform,” CEO Ramy Farid said. The company positions the tool as a way for experienced drug hunters who are not computational chemists to access advanced simulation methods.
Schrodinger partnered with Nvidia and Google Cloud to supply the computational backbone. Early customers get access to the Nvidia Blackwell platform on Google Cloud, integrating Nvidia’s BioNeMo toolkit for biology AI. Full commercial rollout is expected by the end of 2026.
The launch marks a strategic shift for Farid, who had previously warned against AI hype in drug development. Bunsen represents the company’s answer to the growing wave of agentic AI tools entering the pharmaceutical R&D market.
